Compile Data Set for Download or QSAR
Report error Found 178 Enz. Inhib. hit(s) with all data for entry = 9273
TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454519(US10717746, Example 2)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454520(US10717746, Example 3)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454521(US10717746, Example 4)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454525(US10717746, Example 8)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM50528817(CHEMBL4462530 | US10717746, Example 14 | US2023041...)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454533(US10717746, Example 16)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454535(US10717746, Example 18)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454536(US10717746, Example 19)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454536(US10717746, Example 19)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454537(US10717746, Example 20)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454537(US10717746, Example 20)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454538(US10717746, Example 21)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454538(US10717746, Example 21)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454539(US10717746, Example 22)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454540(US10717746, Example 23)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454540(US10717746, Example 23)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454541(US10717746, Example 24)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454542(US10717746, Example 25 | US10717746, Example 84)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454543(US10717746, Example 26)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454544(US10717746, Example 27)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454548(US10717746, Example 31)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454549(US10717746, Example 31a)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454551(US10717746, Example 32)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454552(US10717746, Example 33 | US10717746, Example 35)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454553(US10717746, Example 34)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454552(US10717746, Example 33 | US10717746, Example 35)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454555(US10717746, Example 36)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454556(US10717746, Example 37)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454557(US10717746, Example 38)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454558(US10717746, Example 39)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454559(US10717746, Example 40 | US10717746, Example 41)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454559(US10717746, Example 40 | US10717746, Example 41)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454561(US10717746, Example 42)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454563(US10717746, Example 44)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454564(US10717746, Example 45)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454565(US10717746, Example 46)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454566(US10717746, Example 47)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454567(US10717746, Example 48)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454567(US10717746, Example 48)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454569(US10717746, Example 50)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454570(US10717746, Example 51)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454570(US10717746, Example 51)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454571(US10717746, Example 51a)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454572(US10717746, Example 52)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454573(US10717746, Example 53)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454573(US10717746, Example 53)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454575(US10717746, Example 55)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454575(US10717746, Example 55)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454576(US10717746, Example 56)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Astrazeneca

US Patent
LigandPNGBDBM454577(US10717746, Example 57)
Affinity DataIC50: 3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 178 total ) | Next | Last >>
Jump to: